Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Edema reduction via diuresis is a therapeutic outcome rather than a specific molecular target. It describes the process of mobilizing and excreting excess interstitial fluid through the kidneys by increasing urine production (StatPearls, NBK536944). This physiological effect is primarily achieved using diuretic medications that inhibit specific transporters or receptors along the nephron, such as the Na-K-2Cl cotransporter (NKCC2) in the loop of Henle or the Na-Cl symporter (NCC) in the distal tubule (PubMed, 15191592). Clinically, this process is essential for managing conditions like congestive heart failure, hepatic cirrhosis, and chronic kidney disease, where fluid retention leads to pulmonary or peripheral edema (NIH, PMC4122001). While effective, the process must be carefully monitored to avoid complications such as hypokalemia, hyponatremia, and acute kidney injury. The success of this intervention is often measured by changes in body weight and urine output.
Inhibition of renal ion transporters or hormone receptors to increase solute and water excretion (StatPearls, NBK536944).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Edema reduction via diuresis.